Breaking News Instant updates and real-time market news.

ICPT

Intercept

$98.12

-15.36 (-13.54%)

05:40
09/13/17
09/13
05:40
09/13/17
05:40

Intercept price target lowered to $150 from $240 at Citi

Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $150 saying a "more robust" competitive landscape in both primary biliary cholangitis and nonalcoholic steatohepatitis could limit peak sales of Ocaliva. While the drug appears to be effective and safe in NASH, its overall profile may "not be strong enough to drive a rapid increase" in the NASH diagnosis rate upon approval, limiting the drug's first mover advantage, Beatty tells investors in a research after the company sent a letter to health care providers warning that serious liver injuries, including death, have been reported in primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. Safety concerns are likely to remain an overhang on the shares at least until results from the Phase 3 Regenerate trial in the first half of 2019, which is beyond the 12 month time horizon of the new target price, Beatty writes. He keeps a Buy rating on Intercept. The stock yesterday closed down 13.5%, or $15.36, to $98.12.

ICPT Intercept
$98.12

-15.36 (-13.54%)

09/12/17
SBSH
09/12/17
NO CHANGE
Target $240
SBSH
Buy
Intercept patient safety letter a 'meaningful negative,' says Citi
Citi analyst Joel Beatty calls Intercept Pharmaceuticals' patient safety letter a "meaningful negative" for Intercept Pharmaceuticals. The letter could "dampen physician enthusiasm" to prescribe Ocaliva in primary biliary cholangitis, especially if other competing agents are approved, Beatty tells investors in a research note. He also believes the news is likely to raise investor concerns about the safety of obeticholic acid in nonalcoholic steatohepatitis. The analyst notes that Intercept, when asked, see no impact on the Phase 3 Regenerate trial of OCA in NASH. Intercept in early trading is down 20%, or $22.34, to $91.14. Beatty keeps a Buy rating on the shares with a $240 price target. He notes his price target is largely based on NASH.
09/12/17
CANT
09/12/17
NO CHANGE
Target $69
CANT
Underweight
Cantor reiterates $69 target on Intercept after Ocaliva warning letter
Cantor Fitzgerald analyst Elemer Piros reiterates an Underweight rating on Intercept Pharmaceuticals after the company sent a letter to healthcare providers warning that serious liver injuries, including death, have been reported in liver-impaired primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. The news raises caution on the PBC franchise's future growth potential in more severe patients, and signals a "potential hurdle" for further penetration, Piros tells investors in a research note. Intercept in early trading is down 19% to $92.08.
09/12/17
JEFF
09/12/17
NO CHANGE
JEFF
Intercept selloff an 'overreaction,' says Jefferies
Jefferies analyst Michael Yee said the sell off in Intercept shares is an "overreaction" to the "Dear Healthcare Provider Letter" and said the risk/benefit of OCA remains favorable. The analyst said there is no change to his Buy thesis and $275 price target and would be buyers of the stock and expects shares to recover as the Phase III trial in cirrhotic patients is initiated by year-end and as we approach Phase III NASH results in early 2019.
09/12/17
BARD
09/12/17
NO CHANGE
Target $332
BARD
Outperform
Baird would buy Intercept on weakness
Baird analyst Brian Skorney recommends buying Intercept shares on weakness related to the "Dear Healthcare Provider Letter." The analyst said there is no new information in the letter and serves as a reminder to modify does according to the label for patients with hepatic impairment following cases of Ocaliva being dosed more frequently than recommended. Skorny rates Intercept an Outperform with a $332 price target.

TODAY'S FREE FLY STORIES

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

10:04
01/17/18
01/17
10:04
01/17/18
10:04
Hot Stocks
Exact Sciences drops after release of abstract on possible Cologuard competitor »

Early weakness in shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 26

    Feb

VMW

VMware

$132.75

0.61 (0.46%)

10:02
01/17/18
01/17
10:02
01/17/18
10:02
Conference/Events
VMware management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 19

    Jan

GS

Goldman Sachs

$252.90

-5.33 (-2.06%)

10:01
01/17/18
01/17
10:01
01/17/18
10:01
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs »

Goldman Sachs CFO:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

BAH

Booz Allen

$40.02

0.16 (0.40%)

10:01
01/17/18
01/17
10:01
01/17/18
10:01
Hot Stocks
Booz Allen awarded $165M 5-year contract to support USCYBERCOM »

the General Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CMTL

Comtech

$21.40

-0.58 (-2.64%)

10:01
01/17/18
01/17
10:01
01/17/18
10:01
Hot Stocks
Comtech receives $19.1M follow-on contract »

Comtech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:01
01/17/18
01/17
10:01
01/17/18
10:01
General news
Housing Market Index data reported »

January Housing Market…

ACLS

Axcelis

$30.30

1.15 (3.95%)

, AMAT

Applied Materials

$54.50

1.05 (1.96%)

10:00
01/17/18
01/17
10:00
01/17/18
10:00
Recommendations
Axcelis, Applied Materials analyst commentary  »

Axcelis lowered margin…

ACLS

Axcelis

$30.30

1.15 (3.95%)

AMAT

Applied Materials

$54.50

1.05 (1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

FAST

Fastenal

$55.44

-0.15 (-0.27%)

10:00
01/17/18
01/17
10:00
01/17/18
10:00
Options
Fast action in Fastenal Feb 55s post earnings »

Fast action in Fastenal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

GS

Goldman Sachs

$253.61

-4.855 (-1.88%)

10:00
01/17/18
01/17
10:00
01/17/18
10:00
Hot Stocks
Goldman CFO: Trading facing 'low volatility, low activity' world »

CFO Marty Chavez said on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

MVC

MVC Capital

$10.70

-0.02 (-0.19%)

09:59
01/17/18
01/17
09:59
01/17/18
09:59
Conference/Events
MVC Capital management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

KEYW

KEYW

$6.46

0.09 (1.41%)

09:58
01/17/18
01/17
09:58
01/17/18
09:58
Conference/Events
KEYW management to meet with RBC Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 21

    Feb

  • 22

    Feb

  • 14

    Jun

RIOT

Riot Blockchain

$18.28

-3.6 (-16.45%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Options
Riot Blockchain Inc put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

LRCX

Lam Research

$190.39

1.88 (1.00%)

, MNST

Monster Beverage

$64.56

0.79 (1.24%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Options
Early notable gainers among liquid option names on January 17th »

Notable gainers among…

LRCX

Lam Research

$190.39

1.88 (1.00%)

MNST

Monster Beverage

$64.56

0.79 (1.24%)

IBM

IBM

$167.92

4.07 (2.48%)

IFF

International Flavors

$155.52

2.98 (1.95%)

KLAC

KLA-Tencor

$107.66

0.37 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 24

    Jan

  • 25

    Jan

DIS

Disney

$110.92

0.23 (0.21%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Periodicals
Disney's 'Last Jedi' drops 92% in second weekend at Chinese box office, THR says »

Disney's "Star…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 06

    Feb

AMZN

Amazon.com

$1,304.86

-0.34 (-0.03%)

, HD

Home Depot

$197.20

0.89 (0.45%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Conference/Events
Wedbush retail/hardlines analyst holds an analyst/industry conference call »

Retail/Hardlines Analyst…

AMZN

Amazon.com

$1,304.86

-0.34 (-0.03%)

HD

Home Depot

$197.20

0.89 (0.45%)

LOW

Lowe's

$101.01

0.0371 (0.04%)

W

Wayfair

$84.68

0.18 (0.21%)

WSM

Williams-Sonoma

$54.02

0.17 (0.32%)

BBBY

Bed Bath & Beyond

$23.01

0.19 (0.83%)

TPX

Tempur Sealy

$63.72

-0.075 (-0.12%)

AZO

AutoZone

$780.00

-1.02 (-0.13%)

AAP

Advance Auto Parts

$114.60

0.703 (0.62%)

ORLY

O'Reilly Automotive

$257.89

-0.71 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 08

    Feb

  • 18

    Feb

  • 20

    Feb

  • 22

    Feb

  • 18

    Mar

FB

Facebook

$178.39

-0.98 (-0.55%)

, TWTR

Twitter

$24.52

-0.14 (-0.57%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Committee holds a…

FB

Facebook

$178.39

-0.98 (-0.55%)

TWTR

Twitter

$24.52

-0.14 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

MRK

Merck

$62.32

0.25 (0.40%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Conference/Events
Leerink pharmaceuticals analysts hold an analyst/industry conference call »

Analysts discuss whether…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 23

    Oct

OPGN

OpGen

$0.19

0.0143 (8.29%)

09:55
01/17/18
01/17
09:55
01/17/18
09:55
Conference/Events
OpGen to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

09:54
01/17/18
01/17
09:54
01/17/18
09:54
General news
Market opens with gains, but holding them will be the focus »

Stock futures were higher…

ACLS

Axcelis

$30.30

1.15 (3.95%)

09:53
01/17/18
01/17
09:53
01/17/18
09:53
Hot Stocks
Breaking Hot Stocks news story on Axcelis »

Axcelis drops 5% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

XLF

Financial Select Sector

$29.16

0.01 (0.03%)

, XLE

Energy Select Sector SPDR

$76.69

0.25 (0.33%)

09:52
01/17/18
01/17
09:52
01/17/18
09:52
Technical Analysis
Technical Take: S&P 500 moves moderately higher, sector breadth mixed »

The S&P 500 (SPX) was…

XLF

Financial Select Sector

$29.16

0.01 (0.03%)

XLE

Energy Select Sector SPDR

$76.69

0.25 (0.33%)

XLI

Industrial Select Sector SPDR

$79.59

0.14 (0.18%)

XLK

Technology Select Sector SPDR

$66.91

0.36 (0.54%)

XLP

Consumer Staples Sector SPDR

$57.23

0.32 (0.56%)

XLV

Health Care Select Sector SPDR

$87.53

0.28 (0.32%)

SPY

SPDR S&P 500 ETF Trust

$277.86

0.89 (0.32%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QADB

QAD Inc

$31.80

0.05 (0.16%)

09:50
01/17/18
01/17
09:50
01/17/18
09:50
Hot Stocks
Breaking Hot Stocks news story on QAD Inc 

QAD Inc trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITIC

Investors Title Company

$199.00

3.26 (1.67%)

09:50
01/17/18
01/17
09:50
01/17/18
09:50
Hot Stocks
Breaking Hot Stocks news story on Investors Title Company »

Investors Title Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$57.07

0.16 (0.28%)

09:45
01/17/18
01/17
09:45
01/17/18
09:45
Technical Analysis
Technical Take: Consumer Staples Sector SPDR nearing breakout »

The Consumer Staples…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QADB

QAD Inc

$31.80

0.05 (0.16%)

09:45
01/17/18
01/17
09:45
01/17/18
09:45
Hot Stocks
Breaking Hot Stocks news story on QAD Inc »

QAD Inc trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.